Dendritic cells supply IL-2 for gain of Treg function in vitro (102.14)

Mohamed Elmahadi Nasr
DOI: https://doi.org/10.4049/jimmunol.178.supp.102.14
2007-04-01
The Journal of Immunology
Abstract:Abstract The CD4+CD25+ regulatory T cell plays an important role in controlling immunity to self and foreign antigens. CD4+CD25+ require T cell receptor and IL-2 receptor activation for in vivo development/ expansion, in vitro expansion and for in vitro function, but the source of IL-2 remains unknown. we used the DO11.10 transgenic mouse model, whose T cell receptor shows allogeneic cross-reactivity to B6. Purified dendritic cells from WT or IL-2 −/− B6 were labeled with cell tracker green and cultured overnight with natural CD4+CD25+ Tregs from DO11.10 transgenic mice, the RD6 inhibitory hybridoma, or the control RD6N non-inhibitory hybridoma. DCs were FACS sorted then used to stimulate fresh CD4+CD25− DO11.10 effectors T cells in an IL-2 ELISPOT assay. CD4+CD25+ cells suppressed CD4+CD25− effectors cells up to 90% when stimulated with WT dendritic cells, but only 29% when stimulated with IL-2 −/− DCs. Similar results were obtained using the RD6 inhibitory hybridoma> RD6 suppressed a mean of 97% with WT dendritic cells and only 25% with IL-2 −/− dendritic cells. The result supports a model that Tregs require signal 3 activation for the APC to gain inhibitory function.
immunology
What problem does this paper attempt to address?